{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:22:09Z","timestamp":1793388129548,"version":"4.5.0"},"reference-count":247,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":266,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Physiological Sciences"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1186\/s12576-024-00933-4","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T09:02:27Z","timestamp":1727082147000},"page":"46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5418-2191","authenticated-orcid":false,"given":"Noha N.","family":"Lasheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2749-8982","authenticated-orcid":false,"given":"Salma","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0717-9225","authenticated-orcid":false,"given":"Abdullrahman","family":"Elgarawany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1124-8084","authenticated-orcid":false,"given":"Darin W.","family":"Aswa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8820-5480","authenticated-orcid":false,"given":"Rana","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6402-0625","authenticated-orcid":false,"given":"Ziad","family":"Farouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1186\/s12576-024-00933-4_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchemneu.2022.102210","article-title":"Cellular mechanisms in brain aging: focus on physiological and pathological aging","volume":"128","author":"Aguilar-Hern\u00e1ndez","year":"2023","journal-title":"J Chem Neuroanat"},{"key":"10.1186\/s12576-024-00933-4_bb0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1089\/ars.2020.8071","article-title":"From development to aging: the path to cellular senescence","volume":"34","author":"Sacco","year":"2021","journal-title":"Antioxid Redox Signal"},{"key":"10.1186\/s12576-024-00933-4_bb0020","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1002\/bjs.10053","article-title":"Molecular and biological hallmarks of ageing","volume":"103","author":"Aunan","year":"2016","journal-title":"Br J Surg"},{"key":"10.1186\/s12576-024-00933-4_bb0025","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2005.11.020","article-title":"Short telomeres, even in the presence of telomerase, limit tissue renewal capacity","volume":"123","author":"Hao","year":"2005","journal-title":"Cell"},{"key":"10.1186\/s12576-024-00933-4_bb0030","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cell.2012.01.039","article-title":"Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases","volume":"148","author":"Ding","year":"2012","journal-title":"Cell"},{"key":"10.1186\/s12576-024-00933-4_bb0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-022-00751-y","article-title":"DNA damage and repair in age-related inflammation","volume":"23","author":"Zhao","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1186\/s12576-024-00933-4_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112679","article-title":"Balancing DNA repair to prevent ageing and cancer","volume":"405","author":"Stead","year":"2021","journal-title":"Exp Cell Res"},{"key":"10.1186\/s12576-024-00933-4_bb0045","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.tibs.2022.03.008","article-title":"Mitochondrial-to-nuclear communication in aging: an epigenetic perspective","volume":"47","author":"Zhu","year":"2022","journal-title":"Trends Biochem Sci"},{"key":"10.1186\/s12576-024-00933-4_bb0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cell.2020.08.009","article-title":"Targeting mitochondria-located circRNA SCAR alleviates NASH via reducing mROS output","volume":"183","author":"Zhao","year":"2020","journal-title":"Cell"},{"key":"10.1186\/s12576-024-00933-4_bb0055","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12935","article-title":"NAD+ supplementation rejuvenates aged gut adult stem cells","volume":"18","author":"Igarashi","year":"2019","journal-title":"Aging Cell"},{"key":"10.1186\/s12576-024-00933-4_bb0060","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-020-00311-7","article-title":"NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1186\/s12576-024-00933-4_bb0065","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1002\/1878-0261.13269","article-title":"Autophagy at the intersection of aging, senescence, and cancer","volume":"16","author":"Cassidy","year":"2022","journal-title":"Mol Oncol"},{"key":"10.1186\/s12576-024-00933-4_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101468","article-title":"Autophagy and the hallmarks of aging","volume":"72","author":"Kaushik","year":"2021","journal-title":"Ageing Res Rev"},{"key":"10.1186\/s12576-024-00933-4_bb0075","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.cell.2019.01.040","article-title":"Quiescence modulates stem cell maintenance and regenerative capacity in the aging brain","volume":"176","author":"Kalamakis","year":"2019","journal-title":"Cell"},{"key":"10.1186\/s12576-024-00933-4_bb0080","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.cell.2021.03.005","article-title":"The aging lung: physiology, disease, and immunity","volume":"184","author":"Schneider","year":"2021","journal-title":"Cell"},{"key":"10.1186\/s12576-024-00933-4_bb0085","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jn\/nxy263","article-title":"Dose-dependent increases in whole-body net protein balance and dietary protein-derived amino acid incorporation into myofibrillar protein during recovery from resistance exercise in older men","volume":"149","author":"Holwerda","year":"2019","journal-title":"J Nutr"},{"key":"10.1186\/s12576-024-00933-4_bb0090","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cell.2015.06.023","article-title":"The Ras-Erk-ETS-signaling pathway is a drug target for longevity","volume":"162","author":"Slack","year":"2015","journal-title":"Cell"},{"key":"10.1186\/s12576-024-00933-4_bb0095","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tcb.2020.05.003","article-title":"Classical and nonclassical intercellular communication in senescence and ageing","volume":"30","author":"Fafi\u00e1n-Labora","year":"2020","journal-title":"Trends Cell Biol"},{"key":"10.1186\/s12576-024-00933-4_bb0100","doi-asserted-by":"crossref","first-page":"2002825","DOI":"10.1002\/advs.202002825","article-title":"Engineered tools to study intercellular communication","volume":"8","author":"Yang","year":"2021","journal-title":"Adv Sci"},{"key":"10.1186\/s12576-024-00933-4_bb0105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature10357","article-title":"The ageing systemic milieu negatively regulates neurogenesis and cognitive function","volume":"477","author":"Villeda","year":"2011","journal-title":"Nature"},{"key":"10.1186\/s12576-024-00933-4_bb0110","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.chom.2020.07.013","article-title":"The gut microbiota and unhealthy aging: disentangling cause from consequence","volume":"28","author":"DeJong","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1186\/s12576-024-00933-4_bb0115","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.4103\/1673-5374.335837","article-title":"The influence of gut microbiota alteration on age-related neuroinflammation and cognitive decline","volume":"17","author":"Alsegiani","year":"2022","journal-title":"Neural Regen Res"},{"key":"10.1186\/s12576-024-00933-4_bb0120","unstructured":"Ageing and health. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health. Accessed 16 Sep 2023"},{"key":"10.1186\/s12576-024-00933-4_bb0125","unstructured":"Dementia. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia. Accessed 16 Sep 2023"},{"key":"10.1186\/s12576-024-00933-4_bb0130","doi-asserted-by":"crossref","unstructured":"Hurd MD, Martorell P, Langa KM (2013) Monetary costs of dementia in the United States. N Engl J Med 369:489\u2013490. https:\/\/doi.org\/10.1056\/NEJMc1305541","DOI":"10.1056\/NEJMc1305541"},{"key":"10.1186\/s12576-024-00933-4_bb0135","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/ncb1104-1054","article-title":"Cell biology of protein misfolding: the examples of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"6","author":"Selkoe","year":"2004","journal-title":"Nat Cell Biol"},{"key":"10.1186\/s12576-024-00933-4_bb0140","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1126\/science.1067122","article-title":"Toxic proteins in neurodegenerative disease","volume":"296","author":"Taylor","year":"2002","journal-title":"Science"},{"key":"10.1186\/s12576-024-00933-4_bb0145","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","article-title":"Alzheimer\u2019s disease","volume":"377","author":"Ballard","year":"2011","journal-title":"Lancet Lond Engl"},{"key":"10.1186\/s12576-024-00933-4_bb0150","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1212\/WNL.0000000000009816","article-title":"Healthy lifestyle and the risk of Alzheimer dementia: findings from 2 longitudinal studies","volume":"95","author":"Dhana","year":"2020","journal-title":"Neurology"},{"key":"10.1186\/s12576-024-00933-4_bb0155","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13122","article-title":"Hypothesis review: Alzheimer\u2019s overture guidelines","volume":"33","author":"Ferrer","year":"2023","journal-title":"Brain Pathol"},{"key":"10.1186\/s12576-024-00933-4_bb0160","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1186\/s12576-024-00933-4_bb0165","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev.me.36.020185.002025","article-title":"Alzheimer\u2019s disease","volume":"36","author":"Price","year":"1985","journal-title":"Annu Rev Med"},{"key":"10.1186\/s12576-024-00933-4_bb0170","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer\u2019s disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.1186\/s12576-024-00933-4_bb0175","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0896-6273(02)00794-8","article-title":"Inflammation in neurodegenerative disease\u2014a double-edged sword","volume":"35","author":"Wyss-Coray","year":"2002","journal-title":"Neuron"},{"key":"10.1186\/s12576-024-00933-4_bb0180","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1186\/s12576-024-00933-4_bb0185","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W","article-title":"Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer\u2019s disease","volume":"48","author":"Weiner","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb0190","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archneur.2008.65.7.nct70006","article-title":"Cognitive function over time in the Alzheimer\u2019s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib","volume":"65","author":"ADAPT Research Group","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb0195","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1212\/01.wnl.0000313813.48505.86","article-title":"Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology","volume":"70","author":"Arvanitakis","year":"2008","journal-title":"Neurology"},{"key":"10.1186\/s12576-024-00933-4_bb0200","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1212\/WNL.0b013e3181a18691","article-title":"Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort","volume":"72","author":"Breitner","year":"2009","journal-title":"Neurology"},{"key":"10.1186\/s12576-024-00933-4_bb0205","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after A\u03b242 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1186\/s12576-024-00933-4_bb0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1474-4422(02)00023-6","article-title":"Dosing in phase II trial of Alzheimer\u2019s vaccine suspended","volume":"1","author":"Senior","year":"2002","journal-title":"Lancet Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb0215","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1186\/s12576-024-00933-4_bb0220","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1186\/s12576-024-00933-4_bb0225","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson\u2019s disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1186\/s12576-024-00933-4_bb0230","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","article-title":"Parkinson disease: from pathology to molecular disease mechanisms","volume":"62","author":"Dexter","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1186\/s12576-024-00933-4_bb0235","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1056\/NEJM199601113340202","article-title":"Prevalence of parkinsonian signs and associated mortality in a community population of older people","volume":"334","author":"Bennett","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1186\/s12576-024-00933-4_bb0240","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mds.21766","article-title":"Parkinson\u2019s disease and aging: same or different process?","volume":"23","author":"Hawkes","year":"2008","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"10.1186\/s12576-024-00933-4_bb0245","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.neuro.22.1.123","article-title":"Etiology and pathogenesis of Parkinson\u2019s disease","volume":"22","author":"Olanow","year":"1999","journal-title":"Annu Rev Neurosci"},{"key":"10.1186\/s12576-024-00933-4_bb0250","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1186\/s12576-024-00933-4_bb0255","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"Alpha-Synuclein locus triplication causes Parkinson\u2019s disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1186\/s12576-024-00933-4_bb0260","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1186\/s12576-024-00933-4_bb0265","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease","volume":"51","author":"Gibb","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1186\/s12576-024-00933-4_bb0270","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1750-1326-4-9","article-title":"Alpha-Synuclein and neuronal cell death","volume":"4","author":"Cookson","year":"2009","journal-title":"Mol Neurodegen"},{"key":"10.1186\/s12576-024-00933-4_bb0275","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00401-007-0227-4","article-title":"More frequent Lewy bodies but less frequent Alzheimer-type lesions in multiple system atrophy as compared to age-matched control brains","volume":"114","author":"Jellinger","year":"2007","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1186\/s12576-024-00933-4_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008784","article-title":"Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson\u2019s disease","volume":"5","author":"Sanchez-Guajardo","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1186\/s12576-024-00933-4_bb0285","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.immuni.2014.06.013","article-title":"Origin and functions of tissue macrophages","volume":"41","author":"Epelman","year":"2014","journal-title":"Immunity"},{"key":"10.1186\/s12576-024-00933-4_bb0290","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1146\/annurev-cellbio-100616-060509","article-title":"Microglia and the brain: complementary partners in development and disease","volume":"34","author":"Hammond","year":"2018","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1186\/s12576-024-00933-4_bb0295","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/nn1997","article-title":"Microglia: active sensor and versatile effector cells in the normal and pathologic brain","volume":"10","author":"Hanisch","year":"2007","journal-title":"Nat Neurosci"},{"key":"10.1186\/s12576-024-00933-4_bb0300","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1126\/science.1110647","article-title":"Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo","volume":"308","author":"Nimmerjahn","year":"2005","journal-title":"Science"},{"key":"10.1186\/s12576-024-00933-4_bb0305","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.neuron.2012.03.026","article-title":"Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner","volume":"74","author":"Schafer","year":"2012","journal-title":"Neuron"},{"key":"10.1186\/s12576-024-00933-4_bb0310","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/glia.10319","article-title":"Dystrophic microglia in the aging human brain","volume":"45","author":"Streit","year":"2004","journal-title":"Glia"},{"key":"10.1186\/s12576-024-00933-4_bb0315","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00401-009-0556-6","article-title":"Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer\u2019s disease","volume":"118","author":"Streit","year":"2009","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1186\/s12576-024-00933-4_bb0320","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neurobiolaging.2020.12.003","article-title":"Dystrophic microglia are associated with neurodegenerative disease and not healthy aging in the human brain","volume":"99","author":"Shahidehpour","year":"2021","journal-title":"Neurobiol Aging"},{"key":"10.1186\/s12576-024-00933-4_bb0325","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fnagi.2017.00277","article-title":"Key aging-associated alterations in primary microglia response to beta-amyloid stimulation","volume":"9","author":"Caldeira","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1186\/s12576-024-00933-4_bb0330","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.arr.2016.11.002","article-title":"Stem cell therapies in age-related neurodegenerative diseases and stroke","volume":"34","author":"Wang","year":"2017","journal-title":"Ageing Res Rev"},{"key":"10.1186\/s12576-024-00933-4_bb0335","first-page":"70","article-title":"Stem cell therapy for neurological disorders","volume":"109","author":"Alessandrini","year":"2019","journal-title":"S Afr Med J Suid-Afr Tydskr Vir Geneeskd"},{"key":"10.1186\/s12576-024-00933-4_bb0340","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.4252\/wjsc.v13.i9.1278","article-title":"Neural stem cell therapy for brain disease","volume":"13","author":"Zhao","year":"2021","journal-title":"World J Stem Cells"},{"key":"10.1186\/s12576-024-00933-4_bb0345","doi-asserted-by":"crossref","first-page":"1139359","DOI":"10.3389\/fbioe.2023.1139359","article-title":"Mesenchymal stem cell therapy for neurological disorders: the light or the dark side of the force?","volume":"11","author":"Isakovi\u0107","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1186\/s12576-024-00933-4_bb0350","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.4252\/wjsc.v13.i9.1215","article-title":"Recent advances in stem cell therapy for neurodegenerative disease: three dimensional tracing and its emerging use","volume":"13","author":"Kim","year":"2021","journal-title":"World J Stem Cells"},{"key":"10.1186\/s12576-024-00933-4_bb0355","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12929-021-00725-7","article-title":"Mesenchymal stem\/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications","volume":"28","author":"Zhuang","year":"2021","journal-title":"J Biomed Sci"},{"key":"10.1186\/s12576-024-00933-4_bb0360","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3390\/cells11091464","article-title":"Interaction of neural stem cells (NSCs) and mesenchymal stem cells (MSCs) as a promising approach in brain study and nerve regeneration","volume":"11","author":"Kaminska","year":"2022","journal-title":"Cells"},{"key":"10.1186\/s12576-024-00933-4_bb0365","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2740","article-title":"A review of stem cell therapy: an emerging treatment for dementia in Alzheimer\u2019s and Parkinson\u2019s disease","volume":"12","author":"Pradhan","year":"2022","journal-title":"Brain Behav"},{"key":"10.1186\/s12576-024-00933-4_bb0370","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3390\/cells11111732","article-title":"Alpha-synuclein aggregation pathway in Parkinson\u2019s disease: current status and novel therapeutic approaches","volume":"11","author":"Vidovi\u0107","year":"2022","journal-title":"Cells"},{"key":"10.1186\/s12576-024-00933-4_bb0375","unstructured":"Neuroglia\u2014an overview | ScienceDirect Topics. https:\/\/www.sciencedirect.com\/topics\/veterinary-science-and-veterinary-medicine\/neuroglia. Accessed 20 Jun 2024"},{"key":"10.1186\/s12576-024-00933-4_bb0380","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1590\/s1679-45082017rb4024","article-title":"Gene therapy: advances, challenges and perspectives","volume":"15","author":"Gon\u00e7alves","year":"2017","journal-title":"Einstein Sao Paulo Braz"},{"key":"10.1186\/s12576-024-00933-4_bb0385","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/0022034509337480","article-title":"Gene therapy","volume":"88","author":"Scheller","year":"2009","journal-title":"J Dent Res"},{"key":"10.1186\/s12576-024-00933-4_bb0390","first-page":"3","article-title":"Barriers to liposomal gene delivery: from application site to the target","volume":"15","author":"Saffari","year":"2016","journal-title":"Iran J Pharm Res IJPR"},{"key":"10.1186\/s12576-024-00933-4_bb0395","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JAD-180422","article-title":"Neuro-immuno-gene- and genome-editing-therapy for Alzheimer\u2019s disease: are we there yet?","volume":"65","author":"Raikwar","year":"2018","journal-title":"J Alzheimers Dis JAD"},{"key":"10.1186\/s12576-024-00933-4_bb0400","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.nbd.2003.07.005","article-title":"A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer\u2019s disease","volume":"14","author":"Zhang","year":"2003","journal-title":"Neurobiol Dis"},{"key":"10.1186\/s12576-024-00933-4_bb0405","doi-asserted-by":"crossref","unstructured":"Axelsen TM, Woldbye DPD gene therapy for Parkinson\u2019s disease\u2014an update. J Park Dis 8:195\u2013215. https:\/\/doi.org\/10.3233\/JPD-181331","DOI":"10.3233\/JPD-181331"},{"key":"10.1186\/s12576-024-00933-4_bb0410","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.27414","article-title":"Targeted therapies for Parkinson\u2019s disease: from genetics to the clinic","volume":"33","author":"Sardi","year":"2018","journal-title":"Mov Disord"},{"key":"10.1186\/s12576-024-00933-4_bb0415","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/md21030144","article-title":"Potential active marine peptides as anti-aging drugs or drug candidates","volume":"21","author":"Yang","year":"2023","journal-title":"Mar Drugs"},{"key":"10.1186\/s12576-024-00933-4_bb0420","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.730048","article-title":"Adverse effects of metformin from diabetes to COVID-19, cancer, neurodegenerative diseases, and aging: is VDAC1 a common target?","volume":"12","author":"Shoshan-Barmatz","year":"2021","journal-title":"Front Physiol"},{"key":"10.1186\/s12576-024-00933-4_bb0425","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/gerona\/glw090","article-title":"Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island","volume":"71","author":"Arriola Apelo","year":"2016","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1186\/s12576-024-00933-4_bb0430","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3390\/ijms21062084","article-title":"Potential adverse effects of resveratrol: a literature review","volume":"21","author":"Shaito","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1186\/s12576-024-00933-4_bb0435","doi-asserted-by":"crossref","first-page":"iqad004","DOI":"10.1093\/oxfimm\/iqad004","article-title":"The ageing immune system as a potential target of senolytics","volume":"4","author":"Du","year":"2023","journal-title":"Oxf Open Immunol"},{"key":"10.1186\/s12576-024-00933-4_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.877936","article-title":"PD-1\/PD-L axis in neuroinflammation: new insights","author":"Manenti","year":"2022","journal-title":"Front Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb0445","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001460","article-title":"Rethinking immune checkpoint blockade: \u2018beyond the T cell","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1186\/s12576-024-00933-4_bb0450","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1186\/s12576-024-00933-4_bb0455","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 blockade in cancer immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1186\/s12576-024-00933-4_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.785153","article-title":"Current progress and future perspectives of immune checkpoint in cancer and infectious diseases","author":"Cai","year":"2021","journal-title":"Front Genet"},{"key":"10.1186\/s12576-024-00933-4_bb0465","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1186\/s12576-024-00933-4_bb0470","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"10.1186\/s12576-024-00933-4_bb0475","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","article-title":"PD-1 blockade enhances T-cell migration to tumors by elevating IFN-\u03b3 inducible chemokines","volume":"72","author":"Peng","year":"2012","journal-title":"Cancer Res"},{"key":"10.1186\/s12576-024-00933-4_bb0480","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"10.1186\/s12576-024-00933-4_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104258","article-title":"Understanding and overcoming the resistance of cancer to PD-1\/PD-L1 blockade","volume":"145","author":"Shergold","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1186\/s12576-024-00933-4_bb0490","unstructured":"Aristiz\u00e1bal B, Gonz\u00e1lez \u00c1 (2013) Innate immune system. In: Autoimmunity: from bench to bedside [Internet]. El Rosario University Press"},{"key":"10.1186\/s12576-024-00933-4_bb0495","unstructured":"Alberts B, Johnson A, Lewis J, et al (2002) T cells and MHC proteins. In: Molecular biology of the cell. 4th edition. Garland Science"},{"key":"10.1186\/s12576-024-00933-4_bb0500","unstructured":"Informed Health.org (2023) Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006. In brief: The innate and adaptive immune systems. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279396\/"},{"key":"10.1186\/s12576-024-00933-4_bb0505","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41423-020-0470-3","article-title":"Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells","volume":"17","author":"Wu","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1186\/s12576-024-00933-4_bb0510","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.605958","article-title":"Reverse signaling by MHC-I molecules in immune and non-immune cell types","volume":"11","author":"Muntjewerff","year":"2020","journal-title":"Front Immunol"},{"key":"10.1186\/s12576-024-00933-4_bb0515","first-page":"25","article-title":"The CD28\u2013B7 family of co-signaling molecules","author":"Nagai","year":"2019"},{"key":"10.1186\/s12576-024-00933-4_bb0520","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3389\/fimmu.2018.02569","article-title":"T-cell exhaustion in chronic infections: reversing the state of exhaustion and reinvigorating optimal protective immune responses","volume":"9","author":"Saeidi","year":"2018","journal-title":"Front Immunol"},{"key":"10.1186\/s12576-024-00933-4_bb0525","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat Commun"},{"key":"10.1186\/s12576-024-00933-4_bb0530","doi-asserted-by":"crossref","first-page":"10691","DOI":"10.1073\/pnas.0307252101","article-title":"PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells","volume":"101","author":"Latchman","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1186\/s12576-024-00933-4_bb0535","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/ni1165","article-title":"Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4","volume":"6","author":"Probst","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1186\/s12576-024-00933-4_bb0540","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"10.1186\/s12576-024-00933-4_bb0545","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1038\/s41598-018-21861-5","article-title":"FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis","volume":"8","author":"Sambucci","year":"2018","journal-title":"Sci Rep"},{"key":"10.1186\/s12576-024-00933-4_bb0550","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.2147\/OTT.S221340","article-title":"The role Of PD-1\/PD-L1 Axis in treg development and function: implications for cancer immunotherapy","volume":"12","author":"Cai","year":"2019","journal-title":"OncoTargets Ther"},{"key":"10.1186\/s12576-024-00933-4_bb0555","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1186\/s12576-024-00933-4_bb0560","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1186\/s12576-024-00933-4_bb0565","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13129","article-title":"Targeting regulatory T cells in anti-PD-1\/PD-L1 cancer immunotherapy","volume":"95","author":"Zhulai","year":"2022","journal-title":"Scand J Immunol"},{"key":"10.1186\/s12576-024-00933-4_bb0570","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.21037\/atm-20-6719","article-title":"The role of the programmed cell death protein-1\/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review","volume":"8","author":"Zhang","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1186\/s12576-024-00933-4_bb0575","doi-asserted-by":"crossref","first-page":"9331","DOI":"10.1073\/pnas.0710441105","article-title":"Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells","volume":"105","author":"Wang","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1186\/s12576-024-00933-4_bb0580","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1-PD1 axis converts human Th1 cells into regulatory T cells","volume":"3","author":"Amarnath","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1186\/s12576-024-00933-4_bb0585","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.immuni.2018.05.006","article-title":"PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains Foxp3 transcription factor stability in induced regulatory T cells","volume":"49","author":"Stathopoulou","year":"2018","journal-title":"Immunity"},{"key":"10.1186\/s12576-024-00933-4_bb0590","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1186\/s12576-024-00933-4_bb0595","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"10.1186\/s12576-024-00933-4_bb0600","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"10.1186\/s12576-024-00933-4_bb0605","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/eji.201847868","article-title":"PD-1 expression is upregulated on adapted T cells in experimental autoimmune encephalomyelitis but is not required to maintain a hyporesponsive state","volume":"49","author":"Mair","year":"2019","journal-title":"Eur J Immunol"},{"key":"10.1186\/s12576-024-00933-4_bb0610","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1084\/jem.20121416","article-title":"PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis","volume":"210","author":"Zinselmeyer","year":"2013","journal-title":"J Exp Med"},{"key":"10.1186\/s12576-024-00933-4_bb0615","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12264-015-0010-9","article-title":"Programmed death ligand-1 on microglia regulates Th1 differentiation via nitric oxide in experimental autoimmune encephalomyelitis","volume":"32","author":"Hu","year":"2016","journal-title":"Neurosci Bull"},{"key":"10.1186\/s12576-024-00933-4_bb0620","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12974-018-1191-8","article-title":"Impaired CD8 T cell antiviral immunity following acute spinal cord injury","volume":"15","author":"Norden","year":"2018","journal-title":"J Neuroinflamm"},{"key":"10.1186\/s12576-024-00933-4_bb0625","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/glia.22701","article-title":"Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1","volume":"62","author":"Schachtele","year":"2014","journal-title":"Glia"},{"key":"10.1186\/s12576-024-00933-4_bb0630","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/glia.22868","article-title":"Chronic reactive gliosis following regulatory T cell depletion during acute MCMV encephalitis","volume":"63","author":"Lokensgard","year":"2015","journal-title":"Glia"},{"key":"10.1186\/s12576-024-00933-4_bb0635","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/glia.22643","article-title":"Adoptive transfer of cytokine-induced immunomodulatory adult microglia attenuates experimental autoimmune encephalomyelitis in DBA\/1 mice","volume":"62","author":"Zhang","year":"2014","journal-title":"Glia"},{"key":"10.1186\/s12576-024-00933-4_bb0640","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1007\/s11064-019-02864-8","article-title":"Enhanced expression of PD-L1 on microglia after surgical brain injury exerts self-protection from inflammation and promotes neurological repair","volume":"44","author":"Chen","year":"2019","journal-title":"Neurochem Res"},{"key":"10.1186\/s12576-024-00933-4_bb0645","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat Rev Dis Primer"},{"key":"10.1186\/s12576-024-00933-4_bb0650","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement N Y N"},{"key":"10.1186\/s12576-024-00933-4_bb0655","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nm.4022","article-title":"PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer\u2019s disease","volume":"22","author":"Baruch","year":"2016","journal-title":"Nat Med"},{"key":"10.1186\/s12576-024-00933-4_bb0660","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/glia.23260","article-title":"Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-\u03b2 burden in several amyloid transgenic mouse models","volume":"66","author":"Latta-Mahieu","year":"2018","journal-title":"Glia"},{"key":"10.1186\/s12576-024-00933-4_bb0665","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/157340711796817913","article-title":"Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy","volume":"7","author":"Ogawa","year":"2011","journal-title":"Curr Bioact Compd"},{"key":"10.1186\/s12576-024-00933-4_bb0670","first-page":"69","article-title":"MDP and other muropeptides\u2014direct and synergistic effects on the immune system","volume":"12","author":"Traub","year":"2006","journal-title":"J Endotoxin Res"},{"key":"10.1186\/s12576-024-00933-4_bb0675","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/pharmaceutics12100965","article-title":"Carbohydrate immune adjuvants in subunit vaccines","volume":"12","author":"Bashiri","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1186\/s12576-024-00933-4_bb0680","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.3390\/cells11142241","article-title":"Muramyl dipeptide administration delays Alzheimer\u2019s disease physiopathology via NOD2 receptors","volume":"11","author":"Piec","year":"2022","journal-title":"Cells"},{"key":"10.1186\/s12576-024-00933-4_bb0685","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.celrep.2013.10.010","article-title":"Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta","volume":"5","author":"Michaud","year":"2013","journal-title":"Cell Rep"},{"key":"10.1186\/s12576-024-00933-4_bb0690","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.3390\/ijms241310905","article-title":"The synergistic potential of combining PD-1\/PD-L1 immune checkpoint inhibitors with NOD2 agonists in Alzheimer\u2019s disease treatment","volume":"24","author":"Ghareghani","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1186\/s12576-024-00933-4_bb0695","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.733857","article-title":"Amyloid-\u03b2 and \u03b1-synuclein immunotherapy: from experimental studies to clinical trials","volume":"15","author":"Nimmo","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1186\/s12576-024-00933-4_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.08.006","article-title":"An overview of monoclonal antibodies","volume":"35","author":"Bayer","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"10.1186\/s12576-024-00933-4_bb0705","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/cancers13010086","article-title":"Monoclonal antibody-based immunotherapy and its role in the development of cardiac toxicity","volume":"13","author":"Kumar","year":"2020","journal-title":"Cancers"},{"key":"10.1186\/s12576-024-00933-4_bb0710","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2174\/1574892815666200925120717","article-title":"Monoclonal antibodies, bispecific antibodies and antibody-drug conjugates in oncohematology","volume":"15","author":"Mih\u0103il\u0103","year":"2020","journal-title":"Recent Patents Anticancer Drug Discov"},{"key":"10.1186\/s12576-024-00933-4_bb0715","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"key":"10.1186\/s12576-024-00933-4_bb0720","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Gennaro","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1186\/s12576-024-00933-4_bb0725","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"BuddHaeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1186\/s12576-024-00933-4_bb0730","first-page":"9343514","article-title":"Aducanumab therapy to treat Alzheimer\u2019s disease: a narrative review","volume":"2022","author":"Beshir","year":"2022","journal-title":"Int J Alzheimers Dis"},{"key":"10.1186\/s12576-024-00933-4_bb0735","unstructured":"Biogen (2023) A randomized, open-label, parallel-arm study to assess the pharmacokinetic comparability of 2 fixed subcutaneous doses of aducanumab (BIIB037) with a single, weight-based intravenous dose in healthy volunteers. clinicaltrials.gov"},{"key":"10.1186\/s12576-024-00933-4_bb0740","unstructured":"Biogen (2021) A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer\u2019s Disease. clinicaltrials.gov"},{"key":"10.1186\/s12576-024-00933-4_bb0745","unstructured":"Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM\u00ae | Biogen. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/update-phase-4-envision-confirmatory-study-aduhelmr. Accessed 25 Jun 2024"},{"key":"10.1186\/s12576-024-00933-4_bb0750","unstructured":"Biogen (2024) A phase 3b\/4 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to verify the clinical benefit of aducanumab (BIIB037) in participants With Alzheimer\u2019s disease. clinicaltrials.gov"},{"key":"10.1186\/s12576-024-00933-4_bb0755","unstructured":"Biogen (2024) Phase 3b open-label, multicenter, safety study of BIIB037 (Aducanumab) in subjects with Alzheimer\u2019s disease who had previously participated in the Aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205. clinicaltrials.gov"},{"key":"10.1186\/s12576-024-00933-4_bb0760","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck Christopher","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1186\/s12576-024-00933-4_bb0765","unstructured":"Eisai Inc. (2023) A placebo-controlled, double-blind, parallel-group, 18-month study with an open-label extension phase to confirm safety and efficacy of BAN2401 in subjects with early Alzheimer\u2019s disease. clinicaltrials.gov"},{"key":"10.1186\/s12576-024-00933-4_bb0770","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-022-01110-8","article-title":"Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer\u2019s disease","author":"Bateman","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1186\/s12576-024-00933-4_bb0775","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S2666-7568(21)00144-6","article-title":"Donanemab removes Alzheimer\u2019s plaques: what is special about its target?","volume":"2","author":"Alawode","year":"2021","journal-title":"Lancet Healthy Longev"},{"key":"10.1186\/s12576-024-00933-4_bb0780","first-page":"193","article-title":"Chapter 9\u2014biologics for the management of dementia","author":"Chaurasiya","year":"2023"},{"key":"10.1186\/s12576-024-00933-4_bb0785","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.trci.2018.10.001","article-title":"Central pharmacodynamic activity of solanezumab in mild Alzheimer\u2019s disease dementia","volume":"4","author":"Willis","year":"2018","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"10.1186\/s12576-024-00933-4_bb0790","doi-asserted-by":"crossref","first-page":"39374","DOI":"10.1038\/srep39374","article-title":"Structure of crenezumab complex with A\u03b2 shows loss of \u03b2-Hairpin","volume":"6","author":"Ultsch","year":"2016","journal-title":"Sci Rep"},{"key":"10.1186\/s12576-024-00933-4_bb0795","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s40120-023-00541-1","article-title":"immunotherapies targeting amyloid and tau protein in Alzheimer\u2019s disease: should we move away from diseases and focus on biological targets? A systematic review and expert opinion","volume":"12","author":"Esquer","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1186\/s12576-024-00933-4_bb0800","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain J Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb0805","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/brain\/awad151","article-title":"The most valuable player or the tombstone: is tau the correct target to treat Alzheimer\u2019s disease?","volume":"146","author":"Younes","year":"2023","journal-title":"Brain"},{"key":"10.1186\/s12576-024-00933-4_bb0810","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"10.1186\/s12576-024-00933-4_bb0815","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"dopaminergic loss and inclusion body formation in \u03b1-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1186\/s12576-024-00933-4_bb0820","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneur.58.2.186","article-title":"Synucleinopathies: clinical and pathological implications","volume":"58","author":"Galvin","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb0825","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.bcp.2014.01.015","article-title":"Pathogenesis of synaptic degeneration in Alzheimer\u2019s disease and Lewy body disease","volume":"88","author":"Overk","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1186\/s12576-024-00933-4_bb0830","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nrneurol.2010.145","article-title":"Cell-to-cell transmission of non-prion protein aggregates","volume":"6","author":"Lee","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb0835","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrn3887","article-title":"Spreading of pathology in neurodegenerative diseases: a focus on human studies","volume":"16","author":"Brettschneider","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"10.1186\/s12576-024-00933-4_bb0840","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson\u2019s disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"10.1186\/s12576-024-00933-4_bb0845","doi-asserted-by":"crossref","unstructured":"Henderson MX, Covell DJ, Chung CH-Y, Pitkin RM, Sandler RM, Decker SC, Riddle DM, Zhang B, Gathagan RJ, James MJ, Trojanowski JQ, Brunden KR, Lee VMY, Luk KC (2020) Characterization of novel conformation-selective \u03b1-synuclein antibodies as potential immunotherapeutic agents for Parkinson\u2019s disease. Neurobiol Dis 136:104712. https:\/\/doi.org\/10.1016\/j.nbd.2019.104712","DOI":"10.1016\/j.nbd.2019.104712"},{"key":"10.1186\/s12576-024-00933-4_bb0850","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","article-title":"\u0391-synuclein immunotherapy blocks uptake and templated propagation of misfolded \u03b1-synuclein and neurodegeneration","volume":"7","author":"Tran","year":"2014","journal-title":"Cell Rep"},{"key":"10.1186\/s12576-024-00933-4_bb0855","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1186\/s12576-024-00933-4_bb0860","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-016-0410-8","article-title":"Anti-\u03b1-synuclein immunotherapy reduces \u03b1-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy","volume":"5","author":"Spencer","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1186\/s12576-024-00933-4_bb0865","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1126\/science.3140379","article-title":"Single-chain antigen-binding proteins","volume":"242","author":"Bird","year":"1988","journal-title":"Science"},{"key":"10.1186\/s12576-024-00933-4_bb0870","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.csbj.2016.07.003","article-title":"Antibodies inside of a cell can change its outside: can intrabodies provide a new therapeutic paradigm?","volume":"14","author":"Marschall","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1186\/s12576-024-00933-4_bb0875","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.852003","article-title":"Alpha-synuclein targeting therapeutics for Parkinson\u2019s disease and related synucleinopathies","volume":"13","author":"Menon","year":"2022","journal-title":"Front Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb0880","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","article-title":"Therapeutic approaches to target alpha-synuclein pathology","volume":"298","author":"Brundin","year":"2017","journal-title":"Exp Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb0885","first-page":"1489","article-title":"Alpha-synuclein immunization strategies for synucleinopathies in clinical studies: a biological perspective","volume":"19","author":"Knecht","year":"2022","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"10.1186\/s12576-024-00933-4_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104587","article-title":"Immunotherapy in Parkinson\u2019s disease: current status and future directions","volume":"132","author":"Chatterjee","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1186\/s12576-024-00933-4_bb0895","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/bs.irn.2019.06.014","article-title":"New therapeutic approaches to target alpha-synuclein in Parkinson\u2019s disease: the role of immunotherapy","volume":"146","author":"Fern\u00e1ndez-Valle","year":"2019","journal-title":"Int Rev Neurobiol"},{"key":"10.1186\/s12576-024-00933-4_bb0900","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-022-01156-8","article-title":"Correction: novel antibodies detect additional \u03b1-synuclein pathology in synucleinopathies: potential development for immunotherapy","volume":"15","author":"Nimmo","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"10.1186\/s12576-024-00933-4_bb0905","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-015-0008-9","article-title":"Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy","volume":"10","author":"Mandler","year":"2015","journal-title":"Mol Neurodegener"},{"key":"10.1186\/s12576-024-00933-4_bb0910","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J Neurosci"},{"key":"10.1186\/s12576-024-00933-4_bb0915","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J Neurosci"},{"key":"10.1186\/s12576-024-00933-4_bb0920","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00401-021-02381-5","article-title":"Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric \u03b1-synuclein accumulation in the brain and gut","volume":"143","author":"Nimmo","year":"2022","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1186\/s12576-024-00933-4_bb0925","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13195-020-00727-x","article-title":"Novel antibodies detect additional \u03b1-synuclein pathology in synucleinopathies: potential development for immunotherapy","volume":"12","author":"Nimmo","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1186\/s12576-024-00933-4_bb0930","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12868-017-0341-8","article-title":"Early start of progressive motor deficits in Line 61 \u03b1-synuclein transgenic mice","volume":"18","author":"Rabl","year":"2017","journal-title":"BMC Neurosci"},{"key":"10.1186\/s12576-024-00933-4_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1186\/s12576-024-00933-4_bb0940","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12987-018-0093-6","article-title":"Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration","volume":"15","author":"Wang","year":"2018","journal-title":"Fluids Barriers CNS"},{"key":"10.1186\/s12576-024-00933-4_bb0945","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1186\/s12576-024-00933-4_bb0950","doi-asserted-by":"crossref","first-page":"1994690","DOI":"10.1080\/19420862.2021.1994690","article-title":"Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies","volume":"13","author":"Fjord-Larsen","year":"2021","journal-title":"MAbs"},{"key":"10.1186\/s12576-024-00933-4_bb0955","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116841","article-title":"Anti-human \u03b1-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-\u03b1-synuclein rat model of Parkinson\u2019s disease","volume":"10","author":"Shahaduzzaman","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1186\/s12576-024-00933-4_bb0960","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb0965","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.705407","article-title":"A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson\u2019s disease (PASADENA): rationale, design, and baseline data","volume":"12","author":"Pagano","year":"2021","journal-title":"Front Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb0970","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1186\/s12576-024-00933-4_bb0975","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/psp4.12538","article-title":"Phase II dose selection for alpha synuclein-targeting antibody cinpanemab (BIIB054) based on target protein binding levels in the brain","volume":"9","author":"Kuchimanchi","year":"2020","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"10.1186\/s12576-024-00933-4_bb0980","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb0985","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3233\/JPD-212594","article-title":"Safety and tolerability of active immunotherapy targeting \u03b1-synuclein with PD03A in patients with early Parkinson\u2019s disease: a randomized, placebo-controlled, phase 1 study","volume":"11","author":"Poewe","year":"2021","journal-title":"J Parkinson Dis"},{"key":"10.1186\/s12576-024-00933-4_bb0990","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/mds.29016","article-title":"A randomized first-in-human study with UB-312, a UBITh\u00ae \u03b1-synuclein peptide vaccine","volume":"37","author":"Yu","year":"2022","journal-title":"Mov Disord"},{"key":"10.1186\/s12576-024-00933-4_bb0995","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbadis.2016.04.017","article-title":"Common neurodegenerative pathways in obesity, diabetes, and Alzheimer\u2019s disease","volume":"1863","author":"Pugazhenthi","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1186\/s12576-024-00933-4_bb1000","unstructured":"Immune checkpoint inhibitors and their side effects. https:\/\/www.cancer.org\/cancer\/managing-cancer\/treatment-types\/immunotherapy\/immune-checkpoint-inhibitors.html. Accessed 18 Sep 2023"},{"key":"10.1186\/s12576-024-00933-4_bb1005","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1186\/s12576-024-00933-4_bb1010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13578-022-00897-1","article-title":"A change of PD-1\/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer\u2019s Disease","volume":"12","author":"Wu","year":"2022","journal-title":"Cell Biosci"},{"key":"10.1186\/s12576-024-00933-4_bb1015","article-title":"Immune checkpoint molecules-inherited variations as markers for cancer risk","volume":"11","author":"Wagner","year":"2020","journal-title":"Front Immunol"},{"key":"10.1186\/s12576-024-00933-4_bb1020","unstructured":"Can cancer immunotherapy principles be applied to neurodegenerative diseases? In: RD Syst. https:\/\/www.rndsystems.com\/blog\/can-cancer-immunotherapy-principles-be-applied-neurodegenerative-diseases. Accessed 18 Sep 2023"},{"key":"10.1186\/s12576-024-00933-4_bb1025","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1186\/s12576-024-00933-4_bb1030","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/cancers11050624","article-title":"Immune checkpoint ligand reverse signaling: looking back to go forward in cancer therapy","volume":"11","author":"Lecis","year":"2019","journal-title":"Cancers"},{"key":"10.1186\/s12576-024-00933-4_bb1035","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb1040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1186\/s12576-024-00933-4_bb1045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.31887\/DCNS.2019.21.1\/mschwartz","article-title":"Potential immunotherapy for Alzheimer disease and age-related dementia","volume":"21","author":"Schwartz","year":"2019","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1186\/s12576-024-00933-4_bb1050","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2020.20377","article-title":"Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature","volume":"150","author":"Stuby","year":"2020","journal-title":"Swiss Med Wkly"},{"key":"10.1186\/s12576-024-00933-4_bb1055","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1186\/s12576-024-00933-4_bb1060","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/mus.25055","article-title":"Myasthenia gravis exacerbation associated with pembrolizumab","volume":"54","author":"Zhu","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1186\/s12576-024-00933-4_bb1065","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1093\/oncolo\/oyac033","article-title":"Consider myocarditis when patients treated with immune checkpoint inhibitors present with ocular symptoms","volume":"27","author":"Rhee","year":"2022","journal-title":"Oncologist"},{"key":"10.1186\/s12576-024-00933-4_bb1070","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11912-023-01411-7","article-title":"Cardiovascular effects of immune checkpoint inhibitors: more than just myocarditis","volume":"25","author":"Inno","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1186\/s12576-024-00933-4_bb1075","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1186\/s12576-024-00933-4_bb1080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1186\/s12576-024-00933-4_bb1085","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1186\/s12576-024-00933-4_bb1090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12885-018-4051-0","article-title":"Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data","volume":"18","author":"Ma","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1186\/s12576-024-00933-4_bb1095","unstructured":"Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options | Lung Cancer | JAMA Oncology | JAMA Network. https:\/\/jamanetwork.com\/journals\/jamaoncology\/article-abstract\/2526994. Accessed 18 Sep 2023"},{"key":"10.1186\/s12576-024-00933-4_bb1100","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaccao.2022.11.010","article-title":"A new risk factor for cardiovascular events in patients receiving immune checkpoint inhibitor therapy?","volume":"4","author":"Thavendiranathan","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1186\/s12576-024-00933-4_bb1105","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"10.1186\/s12576-024-00933-4_bb1110","first-page":"1","article-title":"Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance","volume":"50","author":"Park","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1186\/s12576-024-00933-4_bb1115","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1186\/s12576-024-00933-4_bb1120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1186\/s12576-024-00933-4_bb1125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-020-00947-6","article-title":"Targeting immune checkpoints in hematological malignancies","volume":"13","author":"Salik","year":"2020","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1186\/s12576-024-00933-4_bb1130","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3390\/ijms23052847","article-title":"Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment","volume":"23","author":"Dobosz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1186\/s12576-024-00933-4_bb1135","unstructured":"Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis | Oncology | JAMA Network Open | JAMA Network. https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2791294#zoi220244r2. Accessed 18 Sep 2023"},{"key":"10.1186\/s12576-024-00933-4_bb1140","article-title":"How we treat neurological toxicity from immune checkpoint inhibitors","volume":"4","author":"Spain","year":"2019","journal-title":"ESMO Open"},{"key":"10.1186\/s12576-024-00933-4_bb1145","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/ijms23031851","article-title":"A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics","volume":"23","author":"Lamptey","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1186\/s12576-024-00933-4_bb1150","unstructured":"Kumar A, Sidhu J, Lui F, Tsao JW (2024) Alzheimer Disease. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"10.1186\/s12576-024-00933-4_bb1155","doi-asserted-by":"crossref","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch1","article-title":"Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis","author":"Kouli","year":"2018"},{"key":"10.1186\/s12576-024-00933-4_bb1160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/sci-2021-063","article-title":"Advances in stem cell therapy in Alzheimer\u2019s disease: a comprehensive clinical trial review","volume":"9","author":"Karvelas","year":"2022","journal-title":"Stem Cell Investig"},{"key":"10.1186\/s12576-024-00933-4_bb1165","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1681\/ASN.2009111156","article-title":"Angiomyeloproliferative lesions following autologous stem cell therapy","volume":"21","author":"Thirabanjasak","year":"2010","journal-title":"J Am Soc Nephrol JASN"},{"key":"10.1186\/s12576-024-00933-4_bb1170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000029","article-title":"Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient","volume":"6","author":"Amariglio","year":"2009","journal-title":"PLoS Med"},{"key":"10.1186\/s12576-024-00933-4_bb1175","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jtcvs.2007.11.068","article-title":"Mesenchymal stem cells engineered to overexpress stem cell factor improve cardiac function but have malignant potential","volume":"136","author":"Fazel","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1186\/s12576-024-00933-4_bb1180","doi-asserted-by":"crossref","first-page":"12549","DOI":"10.1523\/JNEUROSCI.2080-16.2016","article-title":"Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice","volume":"36","author":"Kastanenka","year":"2016","journal-title":"J Neurosci"},{"key":"10.1186\/s12576-024-00933-4_bb1185","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1186\/s12576-024-00933-4_bb1190","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/acn3.469","article-title":"Efficacy and safety of anti-amyloid-\u03b2 immunotherapy for Alzheimer\u2019s disease: a systematic review and network meta-analysis","volume":"4","author":"Mo","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb1195","first-page":"31925","article-title":"Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer\u2019s disease: a comprehensive review","volume":"10","author":"Haddad","year":"2022","journal-title":"Health Psychol Res"},{"key":"10.1186\/s12576-024-00933-4_bb1200","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","article-title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimers Dement N Y N"},{"key":"10.1186\/s12576-024-00933-4_bb1205","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000511506","article-title":"Lessons learnt from the second generation of anti-amyloid monoclonal antibodies clinical trials","volume":"49","author":"Tian Hui Kwan","year":"2020","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1186\/s12576-024-00933-4_bb1210","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/alz.12286","article-title":"Engage and emerge: truth and consequences?","volume":"17","author":"Kuller","year":"2021","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"10.1186\/s12576-024-00933-4_bb1215","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of Aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility","volume":"325","author":"Alexander","year":"2021","journal-title":"JAMA"},{"key":"10.1186\/s12576-024-00933-4_bb1220","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer\u2019s disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimers Dement N Y N"},{"key":"10.1186\/s12576-024-00933-4_bb1225","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","article-title":"Aducanumab produced a clinically meaningful benefit in association with amyloid lowering","volume":"13","author":"Cummings","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1186\/s12576-024-00933-4_bb1230","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1474-4422(08)70063-2","article-title":"Person-centred care of people with severe Alzheimer\u2019s disease: current status and ways forward","volume":"7","author":"Edvardsson","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1186\/s12576-024-00933-4_bb1235","doi-asserted-by":"crossref","first-page":"1169499","DOI":"10.3389\/fnagi.2023.1169499","article-title":"Safety and efficacy of lecanemab for Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized clinical trials","volume":"15","author":"Qiao","year":"2023","journal-title":"Front Aging Neurosci"},{"key":"10.1186\/s12576-024-00933-4_bb1240","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov Disord"}],"container-title":["The Journal of Physiological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12576-024-00933-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12576-024-00933-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1880654625000526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1880654625000526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12576-024-00933-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:25:22Z","timestamp":1762561522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1880654625000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":247,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"alternative-id":["S1880654625000526"],"URL":"https:\/\/doi.org\/10.1186\/s12576-024-00933-4","relation":{},"ISSN":["1880-6546"],"issn-type":[{"value":"1880-6546","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders","name":"articletitle","label":"Article Title"},{"value":"The Journal of Physiological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s12576-024-00933-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"46"}}